drug · small molecule

ONGENTYS

updated 2mo ago

by $AMRX Amneal Pharmaceuticals, Inc.🔗 ChEMBL

community read0 votes

Small molecule drug with a maximum clinical stage of Approval, with an approval for parkinson disease.

targets

Catechol O-methyltransferase

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

ONGENTYS

trade names

Ongentys, Ontilyv

generic

OPICAPONE

MOA

12.1 Mechanism of Action Opicapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT). COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include DOPA, catecholamines (dopamine, norepinephrine, and epinephrine), and their hydroxylated metabolites. When decarboxylation of levodopa is prevented by carbidopa, COMT becomes the major metabolizing enzyme for levodopa, catalyzing its metabolism to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD).

indication

1 INDICATIONS AND USAGE ONGENTYS is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes. ONGENTYS is a catechol-O-methyltransferase (COMT) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes. ( 1 )

ONGENTYS

targets

all catalysts(0)

News(0)

Report a data issue

comments(0)

🐶 often sniffed alongside

Trials studying ONGENTYS